The combination treatment of DM plus the anti-myeloma drugs, BTZ (10 nM), Dex (10uM), lenalidomide (Len) (10uM), or doxorubicin (Dox) (1uM), resulted in synergistic death in both of the drug resistant MM cell lines (Fig. 3e and Fig. S3). This evidence concerns the gene CASC3 and Miyoshi myopathy.